TITLE

Guidelines for the clinical management of familial adenomatous polyposis (FAP)

AUTHOR(S)
Vasen, H. F. A.; Mäslein, G.; Alonso, A.; Aretz, S.; Bernstein, I.; Bertario, L.; Blanco, I.; Bülow, S.; Burn, J.; Capella, G.; Colas, C.; Engel, C.; Frayling, I.; Friedl, W.; Hes, F. J.; Hodgson, S.; Järvinen, H.; Mecklin, J-P; M&3x00F8;ller, P.; Myrh&3x00F8;i, T.
PUB. DATE
May 2008
SOURCE
Gut;May2008, Vol. 57 Issue 5, p704
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Familial adenomatous polyposis (FAP) is a well-described inherited syndrome, which is responsible for <1% of all colorectal cancer (CRC) cases. The syndrome is characterised by the development of hundreds to thousands of adenomas in the colorectum. Almost all patients will develop CRC if they are not identified and treated at an early stage. The syndrome is inherited as an autosomal dominant trait and caused by mutations in the APC gene. Recently, a second gene has been identified that also gives rise to colonic adenomatous polyposis, although the phenotype is less severe than typical FAP. The gene is the MUTYH gene and the inheritance is autosomal recessive. In April 2006 and February 2007, a workshop was organised in Mallorca by European experts on hereditary gastrointestinal cancer aiming to establish guidelines for the clinical management of FAP and to initiate collaborative studies. Thirty-one experts from nine European countries participated in these workshops. Prior to the meeting, various participants examined the most important management issues according to the latest publications. A systematic literature search using Pubmed and reference lists of retrieved articles, and manual searches of relevant articles, was performed. During the workshop, all recommendations were discussed in detail. Because most of the studies that form the basis for the recommendations were descriptive and/or retrospective in nature, many of them were based on expert opinion. The guidelines described herein may be helpful in the appropriate management of FAP families. In order to improve the care of these families further, prospective controlled studies should be undertaken.
ACCESSION #
31931751

 

Related Articles

  • BRCA in breast cancer: ESMO Clinical Recommendations. Balmaña, J.; Díez, O.; Castiglione, M. // Annals of Oncology;May2009 Supplement 4, Vol. 20, piv19 

    The article presents clinical recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer from the European Society for Medical Oncology (ESMO). The prevalence and penetrance of BRCA mutations and familial susceptibility to breast cancer are discussed. Information is...

  • DNA bar code: screening methods of colorectal cancer. McCudden, Christopher; Willis, Monte S. // MLO: Medical Laboratory Observer;Nov2006, Vol. 38 Issue 11, p10 

    The article focuses on the use of DNA bar code screening methods for the detection of colorectal cancer. The majority of DNA tests detect either the loss of tumor-suppressor genes such as TP53 and acetylsalicylic acid phenacetin and caffeine or the activation of oncogenes such as K-ras. To...

  • Identificación de cáncer colorrectal hereditario: Síndrome de Lynch. Ñique-Carbajal, César; Sanchez-Renteria, Fernando; Wernhoff, Patrik; Dominguez-Valentin, Mev // Revista del Cuerpo Médico del Hospital Nacional Almanzor Aguina;2014, Vol. 7 Issue 1, p40 

    Lynch syndrome accounts for approximately 4% of all colorectal cancers. The syndrome follow an autosomal dominant pattern and predisposes individuals to cancer development early in life. Lynch syndrome is caused by mutations in the germline genes encoding proteins responsible for repairing the...

  • Assessing the value of CAN-gene mutations using MALDI-TOF MS. Kohler, Corina; Tavelin, Björn; Fan, Alex; Radpour, Ramin; Barekati, Zeinab; Levi, Fabio; Zhong, Xiao; Lenner, Per; Toniolo, Paolo // Journal of Cancer Research & Clinical Oncology;Aug2011, Vol. 137 Issue 8, p1239 

    Purpose: To identify cancer-linked genes, Sjöblom et al. and Wood et al. performed a genome-wide mutation screening in human breast and colorectal cancers. 140 CAN-genes were found in breast cancer, which in turn contained overall 334 mutations. These mutations could prove useful for...

  • Identification of Lynch Syndrome Among Patients With Colorectal Cancer. Moreira, Leticia; Balaguer, Francesc; Lindor, Noralane; de la Chapelle, Albert; Hampel, Heather; Aaltonen, Lauri A.; Hopper, John L.; Le Marchand, Loic; Gallinger, Steven; Newcomb, Polly A.; Haile, Robert; Thibodeau, Stephen N.; Gunawardena, Shanaka; Jenkins, Mark A.; Buchanan, Daniel D.; Potter, John D.; Baron, John A.; Ahnen, Dennis J.; Moreno, Victor; Andreu, Montserrat // JAMA: Journal of the American Medical Association;10/17/2012, Vol. 308 Issue 15, p1555 

    The article discusses a research for establishing an efficient strategy to identify Lynch Syndrome among the patients suffering from colorectal cancer (CRC). It informs that Lynch Syndrome is the most common form of hereditary CRC which is caused by germ line mutations in DNA mismatch repair...

  • KRAS and BRAF Mutation Screening in Metastatic Colorectal Cancer Costly in Relation to Benefits.  // JNCI: Journal of the National Cancer Institute;Dec2012, Vol. 104 Issue 23, pNP 

    The article discusses research on KRAS and BRAF mutation screening in metastatic colorectal cancer. It references a study by Ajay S. Behl and colleagues, published in the November 28, 2012 issue of the "Journal of the National Cancer Institute." Study authors found that KRAS and BRAF mutations...

  • Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones. Konieczkowski, David J; Garraway, Levi A // Cell Research;Jan2013, Vol. 23 Issue 1, p13 

    Two recent papers identify KRAS activation as a mechanism of acquired resistance to EGFR blockade in colorectal cancer. In doing so, they suggest that resistance to single-agent EGFR blockade will be unavoidable because these alterations exist as latent subclones within the tumor even prior to...

  • Screening of BRCA1 Mutations Using C-terminal Antibody in Sporadic non Familial Colonic Carcinoma. Esmail, Reham Sh.; Sharaf, Walid M.; Helmy, Noha A.; Farrag, Abdel Razik H.; Badawi, Manal A.; Eldin, Amina A. Gamal // Macedonian Journal of Medical Sciences;12/15/2012, Vol. 5 Issue 4, p377 

    Background: Cancer colon is one of the most prevalent cancers in Egypt. Sporadic cancer colon is much more common than familial type; the latter accounting for not more than 30% of the reported cases in different registrations. BRCA1 is a tumor suppressor gene which is proved to be mutated in...

  • High-Resolution Melting Analysis for Rapid Detection of KRAS, BRAF, and PIK3CA Gene Mutations in Colorectal Cancer. Lisa Simi; Nicola Pratesi; Marina Vignoli; Roberta Sestini; Fabio Cianchi; Rosa Valanzano; Stefania Nobili; Enrico Mini; Mario Pazzagli; Claudio Orlando // American Journal of Clinical Pathology;Aug2008, Vol. 130 Issue 2, p247 

    High-resolution melting analysis (HRMA) provides a valid approach to efficiently detect DNA genetic and somatic mutations. In this study, HRMA was used for the screening of 116 colorectal cancers (CRCs) to detect hot-spot mutations in the KRAS and BRAF oncogenes. Mutational hot spots on the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics